OVERVIEW

Finding Your Footing in the Shifting Landscape of Multiple Sclerosis (MS) is organized by CME Outfitters, LLC.

Live Webcast: Wednesday, January 13, 2021
Credit Expiration Date: Thursday, January 13, 2022

CME Accreditation:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners:
Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Statement of Need:
Historically, diagnosing and managing multiple sclerosis (MS) has been difficult. Research uncovering the immune-mediated mechanisms of MS emergence, relapse, and progression has led to development of biomarkers that are now central to diagnosis and treatment decisions, as well as to the development of immune-targeted disease-modifying therapies (DMTs) that can induce long-term remission. Most DMTs are used in continuous or maintenance/escalation therapy regimens, and disease activity typically recurs when these drugs are discontinued. In contrast, pulsed immune reconstitution therapy (IRT) are administered in short courses and provide durable efficacy beyond the active treatment period. This paradigm shift requires healthcare providers (HCPs) to stay up to date on the range of available and emerging therapies for MS and current guidance on treatment selection and the role of biomarkers in the management of patients with MS.

In this CME Outfitters Live and OnDemand webcast, animated 3-D models will illustrate the immune processes that contribute to MS pathology and serve as targets for immune-directed therapies. Expert faculty will review clinical data supporting the efficacy and safety of novel and emerging immune-directed therapies as well as the role of biomarkers in assessing disease progression and guiding treatment decisions in patients with MS.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Identify the immunological mechanisms that contribute to MS.
• Assess clinical data supporting the efficacy and safety of novel and emerging immune-directed therapies for MS.
• Integrate biomarkers and imaging techniques to assess disease progression in patients with MS.

The following learning objectives pertain only to those requesting CNE or CPE credit:
• Identify the immunological mechanisms that contribute to MS.
• Assess clinical data supporting the efficacy and safety of novel and emerging immune-directed therapies for MS.
• Recognize biomarkers and imaging techniques used to assess disease progression in patients with MS.